Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.43 |
| ▸ | MGLL | Q99685 | 9/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4931335 | 0.88 | MGLL (0.38) | CYP4F2CYP4A11MGLL | |
| SCHEMBL4935720 | 0.88 | HPGD (0.45) | MGLLALDH1A1CYP2D6 | |
| SCHEMBL4932632 | 0.85 | CHRNA7 (0.38) | MGLL | |
| SCHEMBL4931192 | 0.85 | MGLL (0.45) | MGLL | |
| SCHEMBL4924280 | 0.85 | MGLL (0.38) | MGLLALDH1A1 | |
| SCHEMBL4926813 | 0.85 | VNN1 (0.39) | MGLLALDH1A1CYP2D6 | |
| SCHEMBL4932048 | 0.85 | MGLL (0.38) | MGLLALDH1A1CYP2D6 | |
| SCHEMBL4923110 | 0.84 | MDM2 (0.62) | MDM2CYP4F2CYP4A11BCL2MCL1 | |
| SCHEMBL4931012 | 0.84 | CHRNA7 (0.39) | MGLLALDH1A1CYP2D6 | |
| SCHEMBL4936031 | 0.84 | MGLL (0.38) | MGLLCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| CN-1980912-A | Pyrazole derivatives | DAIICHI SEIYAKU CO (JP) | 2007-06-13 | — | — | CN | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | MDM2 1935/4885CYP4F2 583/4885CYP4A11 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.